Leukemia
Advertisement
It is now “first and only” bispecific T-cell engager therapy approved for consolidation treatment regardless of MRD ...
Hear expert insights on managing treatment for these patients and the key signs and symptoms to monitor.
There is a “lack of consistency” among patient-reported outcome measures used to evaluate CML treatments.
The analysis of 10 clinical trials and 1 prospective cohort study provides a "benchmark for future studies" of the treatment.
A team studied real-world concordance with NCCN guidelines for diagnostic tests, workup during observation, and treatment.
Even highly educated patients feel "inadequately informed about the purpose, implications, and language around testing."
It was important to develop the model because fatigue has been an "overlooked side effect" due to its "subjective nature."
The label expansion was supported by data from the phase III PhALLCON study.
Educational content focused on the pre-HSCT work-up process, chemotherapy, and transplant admission expectations.
The approval is for pediatric patients older than 1 year with relapsed or refractory CD22-positive B-cell precursor ALL.
Nurses reported that they were “keenly aware of how disruptive the environment is for patients and their families."
Psychosocial care and support are critical parts of cancer care, according to the International Psycho-Oncology Society.
Researchers developed and piloted a novel phone-delivered positive psychology intervention called PATH.
Anastasia Marie Santiago, DNP, APRN, FNP-BC, AOCNP, shares her experiences and several critical pieces of advice.
A clinical trial nurse navigator at The Leukemia & Lymphoma Society discusses real-world data on CLL.
Josie Montegaard, NP, who spoke about CLL at JADPRO Live 2023, discusses how she hopes to see the field move forward.
Anastasia Marie Santiago, DNP, APRN, FNP-BC, AOCNP, explains what Nurse Practitioner Week means to her.
APPs play a vital role in early recognition of symptoms of rheumatologic autoimmune diseases in patients with CLL.
Patients with ibrutinib dose reductions after AEs had longer treatments and similar outcomes to those without reductions.
Patients with CLL who relapsed after HSCT and then received venetoclax achieved outcomes consistent with trial data.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.